Literature DB >> 9684874

Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.

V D Fitzpatrick1, P I Pisacane, R L Vandlen, M X Sliwkowski.   

Abstract

ErbB2 functions as a shared signal transducing component for other ErbB receptor family members. Two of these receptors, ErbB3 and ErbB4, bind the heregulin (HRG) or neuregulin family of polypeptide growth factors. Cells expressing ErbB3 alone display a single class of low affinity HRG binding sites, whereas both high and low affinity binding sites can be measured on cells that co-express both ErbB3 and ErbB2. To assess the interaction of the extracellular domains of ErbB receptors, a series of soluble homodimeric and heterodimeric IgG fusion proteins were constructed. Heregulin binding analysis revealed that a heterodimer composed of either ErbB3 or ErbB4 with ErbB2 is sufficient for the formation of a high affinity binding state. In contrast, heterodimeric ErbB3/4-IgG, as well as homodimeric ErbB3-IgG or ErbB4-IgG, contained only low affinity HRG binding sites. Further evidence for the unique specificity of ErbB2 in generating this high affinity binding site was determined by inhibiting HRG binding with an ErbB2 monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684874     DOI: 10.1016/s0014-5793(98)00737-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

Review 1.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

2.  Immunological Approaches in the Treatment of Metastasized Breast Cancer.

Authors:  Volkmar Müller; Isabell Witzel; Elmar Stickeler
Journal:  Breast Care (Basel)       Date:  2009-12-16       Impact factor: 2.860

3.  The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells.

Authors:  Washa Liu; Katja Zscheppang; Sandy Murray; Heber C Nielsen; Christiane E L Dammann
Journal:  Biochim Biophys Acta       Date:  2007-05-05

4.  Intramembranous valine linked to schizophrenia is required for neuregulin 1 regulation of the morphological development of cortical neurons.

Authors:  Yachi Chen; Melissa L Hancock; Lorna W Role; David A Talmage
Journal:  J Neurosci       Date:  2010-07-07       Impact factor: 6.167

5.  Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.

Authors:  K M Ferguson; P J Darling; M J Mohan; T L Macatee; M A Lemmon
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

6.  Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells.

Authors:  Michio Hiroshima; Yuko Saeki; Mariko Okada-Hatakeyama; Yasushi Sako
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

7.  Neuregulin-1 type III determines the ensheathment fate of axons.

Authors:  Carla Taveggia; George Zanazzi; Ashley Petrylak; Hiroko Yano; Jack Rosenbluth; Steven Einheber; Xiaorong Xu; Raymond M Esper; Jeffrey A Loeb; Peter Shrager; Moses V Chao; Douglas L Falls; Lorna Role; James L Salzer
Journal:  Neuron       Date:  2005-09-01       Impact factor: 17.173

8.  Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.

Authors:  Pei Jin; Juan Zhang; Malgorzata Beryt; Lisa Turin; Cathleen Brdlik; Ying Feng; Xiaomei Bai; Jim Liu; Brett Jorgensen; H Michael Shepard
Journal:  Mol Med       Date:  2008-11-17       Impact factor: 6.354

Review 9.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

10.  An isoform of C/EBPβ, LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration.

Authors:  Bae-Hang Park; Sungho Kook; SeanBong Lee; Jong-Hyeon Jeong; Adam Brufsky; Byeong-Chel Lee
Journal:  J Biol Chem       Date:  2013-08-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.